RxDoctor Payments Data

Itamar Birnbaum, MD

Cardiovascular Disease · Austin, TXNPI 1811254857

Payments from drug & device makers

$18,340in general payments, 2019–2025

Across 599 payments — averaging $30.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$4K
  • Amgen$1K
  • Abiomed$1K
  • Inari Medical, Inc.$1K
  • Boston Scientific$1K
  • Johnson & Johnson$952
  • plus $8K from 45 others

What the payments were for

  • Food & beverage$18,293100%
  • Education$470%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,340 in reported general payments places this provider in the 75th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$174,770
Medicare patients
882
Services billed
2,705

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban271$306,777
XareltoRivaroxaban171$201,687
EntrestoSacubitril/Valsartan104$127,527
CamzyosMavacamten12$96,092
Repatha SureclickEvolocumab88$78,720
FarxigaDapagliflozin Propanediol82$66,834
JardianceEmpagliflozin54$52,791
OzempicSemaglutide33$46,638
MounjaroTirzepatide14$21,288
Praluent PenAlirocumab21$13,317
Metoprolol Succinate332$4,825
Rosuvastatin Calcium414$4,700
Atorvastatin Calcium498$4,537
Nebivolol Hcl55$4,254
Amiodarone Hcl44$3,941

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$359$306,777271 claims
Johnson & JohnsonXarelto$952$201,687171 claims
NovartisEntresto$663$127,527104 claims
E.r. Squibb & Sons, L.L.C.Camzyos$163$96,09212 claims
AstraZenecaFarxiga$705$66,83482 claims
Boehringer IngelheimJardiance$151$52,79154 claims
Novo NordiskOzempic$850$46,63833 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in Austin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →